Skip to main content
SpringerLink
Log in

The 42nd Annual Meeting of The American Society of Clinical Oncology (ASCO)

2–6 June 2006, Atlanta, Georgia, USA

  • Meeting Report
  • Published:
American Journal of Cancer

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Geyer CE, Cameron D, Lindquist D, et al. A phase III randomized, open-label, international study comparing lapatinib and capecitabine vs. capecitabine in women with refractory advanced or metastatic breast cancer (EGF100151) [abstract]. 42nd Annual Meeting of the American Society of Clinical Oncology; 2006 Jun 2–6; Atlanta (GA)

  2. Lueck H, Minckwitz GV, DuBois A, et al. Epirubicin/paclitaxel vs. capecitabine/ paclitaxel in first-line metastatic breast cancer: a prospective, randomized multicentre phase III study of the AGO breast cancer study group [abstract no. 517]. J Clin Oncol 2006; 24Suppl. 18: 7

    Google Scholar 

  3. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006Jun 21; 295(23): 2727–41. Epub 2006 Jun 5

    Article  PubMed  CAS  Google Scholar 

  4. Land SR, Wickerham DL, Costantino JP, et al. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006Jun 21; 295(23): 2742–51

    Article  PubMed  CAS  Google Scholar 

  5. Wickerham DL, Costantino JP, Vogel V, et al. The Study of Tamoxifen and Raloxifene (STAR): initial findings from the NSABP P-2 breast cancer prevention study [abstract no. LBA5]. J Clin Oncol 2006; 24 Suppl. 18: 930

    Google Scholar 

  6. Smith IE, HERA Study Team. Trastuzumab following adjuvant chemotherapy in HER2-positive early breast cancer (HERA trial): disease-free and overall survival after 2 year median follow-up [abstract]. 42nd Annual Meeting of the American Society of Clinical Oncology; 2006 Jun 2–6; Atlanta (GA)

  7. Coombes RC, Paridaens R, Jassem J, et al. First mature analysis of the Intergroup Exemestane Study [abstract no. LBA527]. J Clin Oncol 2006; 24Suppl. 18: 933

    Google Scholar 

  8. Coleman RE, ATAC Trialists’ Group. Effect of anastrozole on bone mineral density: 5-year results from the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial [abstract no. 511]. J Clin Oncol 2006; 24Suppl. 18: 5

    Google Scholar 

  9. Motzer RJ, Hutson TE, Tomczak P, et al. Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa as first-line systemic therapy for patients with metastatic renal cell carcinoma [abstract no. LBA3]. J Clin Oncol 2006; 24Suppl. 18: 930

    Google Scholar 

  10. Hudes G, Carducci M, Tomczak P, et al. A phase 3, randomized, 3-arm study of temsirolimus or interferon-alpha or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma [abstract no. LBA4]. J Clin Oncol 2006; 24Suppl. 18: 930

    Google Scholar 

  11. Shah NP, Rousselot P, Pasquini R, et al. Dasatinib vs high dose imatinib in patients with chronic phase chronic myeloid leukemia resistant to imatinib: results of CA180017 START-R randomized trial [abstract no. 6507]. J Clin Oncol 2006; 24Suppl. 18: 338

    Google Scholar 

  12. Guilhot F, Apperley JF, Shah N, et al. A phase II study of dasatinib in patients with accelerated phase chronic myeloid leukemia who are resistant or intolerant to imatinib: first results of the CA180005 START-A study [abstract no. 39]. Blood 2005; 106(11 Pt 1): 16

    Article  Google Scholar 

  13. Talpaz M, Rousselot P, Kim DW, et al. A phase II study of dasatinib in patients with chronic myeloid leukemia in myeloid blast crisis who are resistant or intolerant to imatinib: first results of the CA180006 START-B study [abstract no. 40]. Blood 2005; 106(11 Pt 1): 16

    Google Scholar 

  14. Hochhaus A, Baccarani M, Sawyers C, et al. Efficacy of dasatinib in patients with chronic phase Philadelphia chromosome-positive CML resistant or intolerant to imatinib: first results of the CA180013 START-C phase II study [abstract]. Blood 2005; 106(Pt 1): 17

    Google Scholar 

  15. Ottmann OG, Martinelli G, Dombret H, et al. A phase II study of dasatinib in patients with chronic myeloid leukemia in lymphoid blast crisis or Philadelphia-chromosome positive acute lymphoblastic leukemia who are resistant or intolerant to imatinib: the START-L CA180015 study [abstract no. 42]. Blood 2005; 106(11 Pt 1): 17

    Google Scholar 

  16. Dmoszynska A, Fetni R, Wang Y, et al. Cytogenetic correlation with efficacy on alemtuzumab vs chlorambucil as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia [abstract no. 6601]. J Clin Oncol 2006; 24Suppl. 18: 361

    Google Scholar 

  17. Burnett AK, Baccarani M, Johnson P, et al. Clofarabine in previously untreated elderly (greater than 65 yrs) AML patients with an unfavourable cytogenetic profile who are considered unfit for standard intensive chemotherapy [abstract no. 6513]. J Clin Oncol 2006; 24Suppl. 18: 340

    Google Scholar 

  18. Fuchs C, Marshall J, Mitchell E, et al. A randomised trial of first-line irinotecan/ fluoropymidine combinations with or without celecoxib in metastatic colorectal cancer (BICC-C) [abstract no. 3506]. J Clin Oncol 2006; 24Suppl. 18: 147

    Google Scholar 

  19. Höchster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin/ fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: final analysis of the TREE-study [abstract no. 3510]. J Clin Oncol 2006; 24Suppl. 18: 148

    Google Scholar 

  20. Berry SR, Cunningham D, Michael M, et al. Preliminary safety of bevacizumab with first-line FOLFOX, CAPOX, FOLFIRI and capecitabine for mCRC: first B.E.A. trial [abstract no. 3534]. J Clin Oncol 2006; 24Suppl. 18: 154

    Google Scholar 

  21. Sugrue M, Kozloff M, Hainsworth J, et al. Risk factors for gastrointestinal perforations in patients with metastatic colorectal cancer receiving bevacizumab plus chemotherapy [abstract no. 3535]. J Clin Oncol 2006; 24 Suppl. 18: 154

    Google Scholar 

  22. Hedrick E, Kozloff M, Hainsworth J, et al. Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: updated results from a large observational registry in the US (BRiTE) [abstract no. 3536]. J Clin Oncol 2006; 24Suppl. 18: 155

    Google Scholar 

  23. Kozloff M, Hainsworth J, Badarinath S, et al. Efficacy of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: updated results from a large observational registry in the US (BRiTE) [abstract no. 3537]. J Clin Oncol 2006; 24Suppl. 18: 155

    Google Scholar 

  24. Labianca R, Floriani I, Cortesi E, et al. Alternating versus continuous FOLFIRI in advanced colorectal cancer: a randomized GISCAD trial [abstract no. 3505]. J Clin Oncol 2006; 24Suppl. 18: 147

    Google Scholar 

  25. Maindrault-Goebel F, Lledo G, Chibaudel B, et al. OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals after FOLFOX in patients with metastatic colorectal cancer. A GERCOR study [abstract no. 3504]. J Clin Oncol 2006; 24Suppl. 18: 147

    Google Scholar 

  26. Facon T, Mary J, Harousseau J, et al. Superiority of melphalan-prednisone + thalidomide over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma [abstract no. 1]. J Clin Oncol 2006; 24Suppl. 18: 1

    Google Scholar 

  27. Rajkumar SV, Hussein M, Catalano J, et al. A multicenter, randomized, double-blind, placebo-controlled trial of thalidomide plus dexamethasone versus dex-amethasone versus dexamethasone alone as initial therapy for newly diagnosed multiple myeloma [abstract no. 7517]. J Clin Oncol 2006; 24Suppl. 18: 426

    Google Scholar 

  28. Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma: results of a North American phase III study (MM-009) [abstract no. 7521]. J Clin Oncol 2006; 24Suppl. 18: 427

    Google Scholar 

  29. Posner MR, Hershock D, Le-Lann L, et al. A phase III trial of docetaxel, cisplatin and 5-fluorouracil versus cisplatin and 5-fluorouracil induction chemotherapy followed by chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck [abstract no. TAX 324]. 42nd Annual Meeting of the American Society of Clinical Oncology; 2006 Jun 2–6; Atlanta (GA)

  30. DeMarinis F, Paul S, Hanna N, et al. Survival update for the phase III study of pemetrexed vs docetaxel in non-small cell lung cancer [abstract no. 7133]. J Clin Oncol 2006; 24Suppl. 18: 397

    Google Scholar 

  31. Fehrenbacher L, O’Neill V, Belani CP, et al. A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer [abstract no. 7062]. J Clin Oncol 2006; 24Suppl. 18: 379

    Google Scholar 

  32. Mehta MP, Gervais R, Chabot P, et al. Motexafin gadolinium combined with prompt whole brain radiation therapy prolongs time to neurologic progression in non-small cell lung cancer patients with brain metastases: results of a phase III trial [abstract no. 7014]. Blood 2005; 106(11 Pt 1): 17

    Google Scholar 

  33. Calais DaSilva FM, Calais DaSilva F, Bono A, et al. Phase III intermittent MAB vs continuous MAB [abstract no. 4513]. J Clin Oncol 2006; 24Suppl. 18: 220

    Google Scholar 

  34. Cunningham D, Rao S, Starling N, et al. Randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer: the REAL 2 trial [abstract no. LBA4017]. J Clin Oncol 2006; 24(Suppl. 18 Pt 2): 18

    Article  Google Scholar 

  35. Kang Y, Kang WK, Shin DB, et al. Randomized phase III trial of capecitabine/ cisplatin vs. continuous infusion of 5-FU/cisplatin as first-line therapy in patients with advanced gastric cancer: efficacy and safety results [abstract no. LBA4018]. J Clin Oncol 2006; 24(Suppl. 18 Pt 2): 934

    Article  Google Scholar 

  36. Al-Batran S, Hartmann JT, Probst S, et al. A randomized phase III trial in patients with advanced adenocarcinoma of the stomach receiving first-line chemotherapy with fluorouracil, leucovorin and oxaliplatin versus fluorouracil, leucovrin and cisplatin [abstract no. LBA4016]. J Clin Oncol 2006; 24(Suppl. 18 Pt 2): 934

    Google Scholar 

  37. Regine WF, Winter KW, Abrams R, et al. RTOG 9704: a phase III study of adjuvant pre and post chemoradiation 5-FU vs. gemcitabine for resected pancreatic adenocarcinoma [abstract no. 4007]. J Clin Oncol 2006; 24Suppl. 18: 180

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adis International Inc., 770 Township Line Road, Suite 300, Yardley, PA, 19067, USA

    William Stow &  Michelle I. Wilde

Authors
  1. William Stow
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michelle I. Wilde
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stow, W., Wilde, M.I. The 42nd Annual Meeting of The American Society of Clinical Oncology (ASCO). Am J Cancer 5, 273–284 (2006). https://doi.org/10.2165/00024669-200605040-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00024669-200605040-00006

Keywords

Search

Navigation